Literature DB >> 12886898

Hemophagocytic syndrome after Kawasaki disease.

Debra L Palazzi1, Kenneth L McClain, Sheldon L Kaplan.   

Abstract

Hemophagocytic syndrome (HPS) is a rare and life-threatening disease in which a generalized histiocytic proliferation results in hemophagocytosis and up-regulation of inflammatory cytokines. This syndrome has been associated with infections, malignancy, drugs and immunologic triggers such as Kawasaki disease (KD). We describe the clinical and laboratory features of two children with HPS after KD and review the three previously reported pediatric cases of recrudescence of HD leading to HPS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12886898

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  9 in total

1.  Forme Fruste of HLH (haemophagocytic lymphohistiocytosis): diagnostic and therapeutic challenges.

Authors:  Susumu Inoue; Chetna Mangat; Yaseen Rafe'e; Mahesh Sharman
Journal:  BMJ Case Rep       Date:  2015-01-29

2.  Hemophagocytosis in the Acute Phase of Fatal Kawasaki Disease in a 4 Month-Old Girl.

Authors:  Vehbi Doğan; Erhan Karaaslan; Samet Özer; Rüveyda Gümüşer; Resul Yılmaz
Journal:  Balkan Med J       Date:  2016-07-01       Impact factor: 2.021

3.  Very high serum ferritin levels in three newborns with Kawasaki-like illness.

Authors:  Arwa Nasir; Hosam Al Tatari; Mohamed A Hamdan
Journal:  Paediatr Child Health       Date:  2012-04       Impact factor: 2.253

Review 4.  How I treat hemophagocytic lymphohistiocytosis.

Authors:  Michael B Jordan; Carl E Allen; Sheila Weitzman; Alexandra H Filipovich; Kenneth L McClain
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

5.  Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality.

Authors:  Tiffany F Lin; Laura L Ferlic-Stark; Carl E Allen; Claudia A Kozinetz; Kenneth L McClain
Journal:  Pediatr Blood Cancer       Date:  2011-01       Impact factor: 3.167

6.  Clinical characteristics of hemophagocytic lymphohistiocytosis following Kawasaki disease: differentiation from recurrent Kawasaki disease.

Authors:  Hae-Ryong Kang; Yong-Hoon Kwon; Eun-Sun Yoo; Kyung-Ha Ryu; Ji Yoon Kim; Heung-Sik Kim; Hwang Min Kim; Young-Ho Lee
Journal:  Blood Res       Date:  2013-12-24

7.  The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).

Authors:  Yasuyo Suzuki; Yasushi Enokido; Kenichiro Yamada; Mie Inaba; Kumiko Kuwata; Naoki Hanada; Tsuyoshi Morishita; Seiji Mizuno; Nobuaki Wakamatsu
Journal:  Oncotarget       Date:  2017-07-11

8.  Differentiation between incomplete Kawasaki disease and secondary hemophagocytic lymphohistiocytosis following Kawasaki disease using N-terminal pro-brain natriuretic peptide.

Authors:  Jung Eun Choi; Yujin Kwak; Jung Won Huh; Eun-Sun Yoo; Kyung-Ha Ryu; Sejung Sohn; Young Mi Hong
Journal:  Korean J Pediatr       Date:  2018-05-28

Review 9.  Understanding organ dysfunction in hemophagocytic lymphohistiocytosis.

Authors:  Caroline Créput; Lionel Galicier; Sophie Buyse; Elie Azoulay
Journal:  Intensive Care Med       Date:  2008-04-22       Impact factor: 41.787

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.